Antibody Dependent Cellular Cytotoxicity (ADCC)
Showing 1 - 25 of >10,000
HER2+ Advanced Breast Cancer, Other Solid Tumors Trial (ADCC-R-Epo-R T-cells + Trastuzumab, Erythropoietin beta, Fludarabine and
Not yet recruiting
- HER2+ Advanced Breast Cancer
- Other Solid Tumors
- ADCC-R-Epo-R T-cells + Trastuzumab
- +2 more
- (no location specified)
Aug 31, 2023
Locally Advanced Breast Cancer, Chemo Effect Trial in Beijing (inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP)
Recruiting
- Locally Advanced Breast Cancer
- Chemotherapy Effect
- inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen
-
Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Feb 28, 2023
Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))
Not yet recruiting
- Lung Cancer
- Non Small Cell Lung Cancer
- Amivantamab 1050mg
- +2 more
-
Aurora, Colorado
- +2 more
Apr 25, 2023
Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical
Completed
- Multiple Myeloma
- +7 more
- Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Nov 2, 2022
Subclass of Donor-specific Antibody asRisk Factor of Antibody
Active, not recruiting
- Antibody-mediated Rejection
-
Montpellier, Hérault, FranceCHU Lapeyronie
Jan 18, 2023
Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum
Not yet recruiting
- Neuromyelitis Optica Spectrum Disorders
- (no location specified)
Sep 29, 2023
Rheumatoid Arthritis, Autoimmune Rheumatologic Disease, Systemic Lupus Erythematosus Trial in Québec (COVID-19 vaccine)
Recruiting
- Rheumatoid Arthritis
- +8 more
- COVID-19 vaccine
-
Montréal, Quebec, Canada
- +1 more
Jan 13, 2023
HIV Infection Trial in New York (Colonoscopy)
Not yet recruiting
- HIV Infection
- Colonoscopy
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Dec 7, 2022
COVID-19 Transmission and Morbidity in Malawi
Recruiting
- SARS CoV 2 Infection
- SARS CoV 2 Vaccination
-
Boston, Massachusetts
- +1 more
Aug 6, 2023
Neuroblastoma Trial in Cologne (antibody ch14.18, GM-CSF, IL-2 i.v.)
Terminated
- Neuroblastoma
- antibody ch14.18
- +4 more
-
Cologne, GermanyUniversity of Cologne
Nov 3, 2022
Castration Resistant Prostate Cancer Trial run by the National Cancer Institute (NCI) (Bintrafusp alfa, N-803, BN-Brachyury)
Not yet recruiting
- Castration Resistant Prostate Cancer
- Bintrafusp alfa
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
SARS-CoV-2-specific Immunity in Individuals Who Have Recovered
Active, not recruiting
- SARS-CoV-2
- COVID-19
- Sample collection
-
Birmingham, Alabama
- +52 more
Sep 3, 2021
HIV Trial in Johannesburg (CH505TF gp120, GLA-SE adjuvant, Placebo)
Recruiting
- HIV Infections
- CH505TF gp120
- +2 more
-
Johannesburg, Gauteng, South AfricaPerinatal HIV Research Unit (PHRU), Soweto CRS
Apr 29, 2022
Cutaneous Squamous Cell Carcinoma Trial in Waratah, Melbourne, Nedlands (Imgatuzumab)
Suspended
- Cutaneous Squamous Cell Carcinoma
-
Waratah, New South Wales, Australia
- +2 more
May 17, 2022
Neuroblastoma Trial in Wien, Greifswald (dinutuximab beta)
Active, not recruiting
- Neuroblastoma
- dinutuximab beta
-
Wien, Austria
- +1 more
Oct 1, 2021
Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma Trial
Completed
- Recurrent Colon Carcinoma
- +41 more
- Cetuximab
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Mar 12, 2020
Malaria Trial in Bagamoyo (SumayaVac-1(SUM-101), Verorab, CHMI)
Not yet recruiting
- Malaria
- SumayaVac-1(SUM-101)
- +2 more
-
Bagamoyo, TanzaniaIfakara Health Institute
Dec 1, 2022
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Trial (Monalizumab, Cetuximab)
Not yet recruiting
- Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
- Monalizumab
- Cetuximab
- (no location specified)
Jan 8, 2023
HIV Trial in San Francisco (DNA CON-S env, IHV01, Placebo)
Withdrawn
- HIV Infections
- DNA CON-S env
- +2 more
-
San Francisco, CaliforniaBridge HIV CRS
Oct 13, 2021
HIV-1-infection Trial in Pathum Wan (VRC07-523LS, PGDM1400LS, N-803)
Not yet recruiting
- HIV-1-infection
- VRC07-523LS
- +7 more
-
Pathum Wan, Bangkok, Thailand
- +1 more
Mar 8, 2023
HER2-positive Breast Cancer, Operable Breast Cancer Trial in France (Trastuzumab + Paclitaxel, Pegfilgrastim)
Recruiting
- HER2-positive Breast Cancer
- Operable Breast Cancer
- Trastuzumab + Paclitaxel
- Pegfilgrastim
-
Avignon, France
- +8 more
Jan 9, 2023
Clear-Cell Renal Carcinoma Trial run by the NCI (rhIL-15, Avelumab)
Terminated
- Clear-Cell Renal Carcinoma
- rhIL-15
- Avelumab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 27, 2022
Olive Leaf Tea Against COVID-19
Completed
- Immunomodulation
- Olive Leaf Tea
-
Konya, Selcuklu, TurkeyTumosan Konya Tractor Factory
Feb 1, 2022
Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid
Completed
- Minimal Residual Disease
- +3 more
- Daratumumab
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Mar 2, 2022